US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Kristin Cavallari, 37, ignores critics of her age
Kristin Cavallari is enjoying a romantic rendezvous with her much younger cowboy lover Mark Estes in2024-05-21EPHRAIM HARDCASTLE: Could William and Harry be reunited at the Duke of Westminster's wedding?
With invitations dispatched for Duke of Westminster Hugh Grosvenor's wedding, a society guessing gam2024-05-21- State visits to Britain have followed more or less the same pattern for well over a century.Take las2024-05-21
'The King and Prince William now face a serious problem'
We’ve been told that Meghan’s syrupy new lifestyle brand ‘will reflect everything she loves – family2024-05-21How Robert F. Kennedy Jr. could make the first debate stage
PHOENIX (AP) — Robert F. Kennedy Jr. has long argued that the biggest hurdle of his presidential cam2024-05-21Who could have saved the Middletons' Party Pieces from disaster? A well
Still reeling from the failure of their Party Pieces mail order business, which collapsed into admin2024-05-21
atest comment